Uniqure N V Quick Ratio (QURE) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Uniqure N v   (NASDAQ: QURE)

Uniqure N V 's Quick Ratio

QURE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Uniqure N V 's Cash & cash equivalent grew by 86.05 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Uniqure N V 's Quick Ratio to 12.78, above Uniqure N v average Quick Ratio.

Within Major Pharmaceutical Preparations industry 265 other companies have achieved higher Quick Ratio than Uniqure N V in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 993 to 1043.

Explain Quick Ratio?
How much Cash & cash equivalents QURE´s has?
What are QURE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/QURE/financial-strength
https://api.csimarket.com/api/v1/companies/QURE/fundamentals
https://api.csimarket.com/api/v1/companies/QURE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
QURE Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -40.24 %
Y / Y Cash & cash equivalent Change 28.7 %
Quick Ratio MRQ 12.78
QURE's Total Ranking # 1043
Seq. Current Liabilities Change -27.84 %
Seq. Cash & cash equivalent Change 86.05 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 266
Healthcare Sector # 446
Overall Market # 1043


Quick Ratio Statistics
High Average Low
24.46 9.81 1.28
(Sep 30 2019)   (Dec 31 2025)




Financial Statements
Uniqure N V 's Current Liabilities $ 60 Millions Visit QURE's Balance sheet
Uniqure N V 's Cash & cash equivalent $ 768 Millions Visit QURE's Balance sheet
Source of QURE's Sales Visit QURE's Sales by Geography


Cumulative Uniqure N V 's Quick Ratio

QURE's Quick Ratio for the trailling 12 Months

QURE Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 28.49 %
Y / Y Cash & cash equivalent TTM Growth 14.24 %
Quick Ratio TTM 5.28
Total Ranking TTM # 2962
Seq. Current Liabilities TTM Growth -13.23 %
Seq. Cash & cash equivalent TTM Growth 13.93 %

Quick ratio ranking by company, industry and sector >> Back to QURE Financial Strength Comparisons >> Go to Compare QURE Quick Ratio to its Competitors

  News about Uniqure N v Quick Ratio

UniQure N.V. Navigating Market Challenges Amid Devastating Conditions,

Reasons Behind UniQure N.V.’s Recent Stock Performance: A Month Overview In a month characterized by mixed market conditions, shares of UniQure N.V. have shown a divergence from broader trends. While the stock has faced struggles, the underlying factors that have shaped its performance warrant careful inspection. In this article, we will examine the recent movements of UniQure s shares, potential market influences, and company-specific news that may explain the company s situation this month.Throughout July 2024, the financial landscape has been tumultuous, marked particularly by the start of the 2024 Olympic Games in Paris. This month commenced with a wave of enthusiasm surrounding the Olympics the unique opening ceremony on the Seine River was a historic moment and drew attention worldwide, bolstering public interest in associated events. However, the exuberance of the Olympics did not translate uniformly across all sectors, including healthcare and biotech, where UniQure operates. The technology and entertainment sectors often garner a more immediate investor attention during such high-profile events, overshadowing the subtle yet significant developments in biopharmaceuticals like those spearheaded by UniQure.

On the trailing twelve months basis QURE Cash & cash equivalent grew by 28.7 % in Q3 2026 year on year, while Current Liabilities plummeted to $60 millions, this led to increase in in Uniqure N V 's Quick Ratio to 5.28, Quick Ratio remained below QURE average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 397 other companies have achieved higher Quick Ratio than Uniqure N V . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2090 to 2962.

Explain Quick Ratio?
How much Cash & cash equivalents QURE´s has?
What are QURE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 398
Healthcare Sector # 809
Within the Market # 2962


trailing twelve months Quick Ratio Statistics
High Average Low
13.79 7.81 3.57
(Mar 31 2022)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Minerva Neurosciences Inc   30.46 $ 76.945  Millions$ 2.526  Millions
Contineum Therapeutics Inc   30.45 $ 244.484  Millions$ 8.028  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Siga Technologies Inc  17.27 $ 116.380  Millions$ 6.738  Millions
Keros Therapeutics Inc   16.36 $ 259.464  Millions$ 15.858  Millions
Design Therapeutics Inc   16.36 $ 208.608  Millions$ 12.753  Millions
Palvella Therapeutics Inc   15.85 $ 236.680  Millions$ 14.928  Millions
Avalo Therapeutics Inc   15.63 $ 392.966  Millions$ 25.135  Millions
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions
Damora Therapeutics Inc   14.72 $ 528.478  Millions$ 35.892  Millions
Protagonist Therapeutics inc   14.42 $ 800.064  Millions$ 55.464  Millions
Praxis Precision Medicines Inc   14.20 $ 745.323  Millions$ 52.498  Millions
Tenax Therapeutics Inc   13.61 $ 113.700  Millions$ 8.355  Millions
Corvus Pharmaceuticals Inc   13.25 $ 204.252  Millions$ 15.418  Millions
Stablecoin Development Corporation  13.01 $ 7.153  Millions$ 0.550  Millions
Uniqure N v   12.78 $ 768.430  Millions$ 60.142  Millions
Rhythm Pharmaceuticals Inc   12.62 $ 320.944  Millions$ 25.438  Millions
Dyne Therapeutics Inc   12.53 $ 1,134.386  Millions$ 90.545  Millions
Sensei Biotherapeutics Inc   12.44 $ 174.795  Millions$ 14.049  Millions
Spyre Therapeutics Inc   12.24 $ 82.727  Millions$ 6.760  Millions

Date modified: 2026-11-06T13:00:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.